Everolimus: Immunosuppression with antilymphoproliferative therapy;Everolimus: Un inmunosupresor con propiedades antiproliferativas

Nefrologia

Volumn 24, Issue 2, 2004, Pages 112-123

  Pascual, J ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 3A; EVEROLIMUS; RAPAMYCIN; TSUKUBAENOLIDE; DRUG DERIVATIVE; FK 506 BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT;

ALLOTRANSPLANTATION; AREA UNDER THE CURVE; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERANCE; HUMAN; INCIDENCE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; REVIEW; STATISTICAL SIGNIFICANCE; ADULT; ANIMAL; CHEMISTRY; CHILD; CLINICAL TRIAL; DRUG EFFECT; DRUG INTERACTION; DRUG SCREENING; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MULTICENTER STUDY; ORGAN TRANSPLANTATION; PRIMATE; RAT;

ADULT; ANIMALS; CHILD; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MULTICENTER STUDIES; ORGAN TRANSPLANTATION; PRIMATES; RATS; SIROLIMUS; TACROLIMUS BINDING PROTEIN 1A; TRANSPLANTATION, HOMOLOGOUS;

EID: 3142718792     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. http://optn.org/latestData/rptData.asp
2. http://msc.es/ont/esp/estadisticas
3. Pascual J: Tratamiento inmunosupresor inicial en trasplante renal. Nefrología 18 (Supl. 6): 104-108, 1998.
4. Ojo AO, Meier-Kriesche HU, Hanson JA, Leitchman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B: Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69: 2405-2409, 2000.
5. Vincenti F, Jensik SC, Filo RS, Millar J, Pirsch J: A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 73: 775-782, 2002.
6. MacDonald AS: The Rapamune Global Study Group. A worldwide, phase III, randmized, controlles safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primery mismatched renal allografts. Transplantation 71: 271-2, 2000.
7. Pascual J, Ortuño J: Nuevos inmunodepresores de inducción en trasplante renal. Med Clin (Barc) 117: 147-157, 2001.
8. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K: Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 326: 789-793, 2003.
9. Schuler W, Sedrani R, Cottens S y cols.: SDZ RAD, a new rapamycin derivative. Pharmacological properties in vitro and in vivo. Transplantation 64: 36-42, 1997.
10. Sedrani R, Cottens S, Kallen J, Schuler W: Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc 30: 2192-2194, 1998.
11. Meier-Kriesche HU, Ojo AO, Hanson JA y cols.: Increased impact of acute rejection in recent era. Transplantation 70: 1098-1100, 2000.
12. Paul LC: Chronic allograft nephropathy: an update. Kidney Int 56: 783-793, 1999.
13. Halloran PF: Call for revolution: a new approach to describing allograft deterioration. Am J Transplant 2: 195-200, 2002.
14. Massy ZA, Guijarro C, Wiederkehr R y cols.: Chronic renal allograft rejection: immunologic and nonimunologic risk factors. Kidney Int 49: 518-524, 1996.
15. Humar A, Kandaswamy R, Hassoun AA y cols.: Immunologie factors-the major risk for long-term renal allograft survival. Transplantation 68: 1842-1846, 1999.
16. Monaco AP, Burke JF Jr, Ferguson RM y cols.: Current thinking on chronic renal allograft rejection: issues, concerns and recommendations from a 1997 roundtable discussion. Am J Kidney Dis 33: 150-160, 1999.
17. Humar A, Kerr S, Gillingham KJ, Matas AJ: Features of acute rejection that increase risk for chronic rejection. Transplantation 68: 1200-1203, 1999.
18. Matas AJ, Humar A, Payne WD y cols.: Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection. Ann Surg 230: 493-500, 1999.
19. Humar A, Gillingham KJ, Payne WD, Dunn DL, Sutherland DER, Matas AJ: Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 68: 1879-1883, 1999.
20. Johnson RWG: The clinical impact of nephrotoxicity in renal transplantation. Transplantation 69: SS14-SS17, 2000.
21. Paul LC, Sijpkens WJ, De Fijter JW: Calcineurin inhibitors and chronic renal allograft dysfunction: not enough or too much? Transplant Rev 15: 82-92, 2001.
22. Nashan B, Cole E, Levy G, Thervet E: Clinical validation studies of Neoral C2 monitoring: a review. Transplantation 73: S3-S11, 2002.
23. Burke JF, Pirsch JD, Ramos EL y cols.: Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 331: 358-363, 1994.
24. Sanders CE, Julián BA, Gaston RS y cols.: Benefits of continued cyclosporine through an indigent drug program. Am J Kidney Dis 28: 572-577, 1996.
25. Jha V, Muthukumar R, Kohli HS y cols.: Impact of cyclosporine withdrawal on living-related renal transplants: a single center experience. Am J Kidney Dis 37: 160-163, 2001.
26. Böhler T, Waiser J, Budde K y cols.: The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant Proc 30: 2195-2197, 1998.
27. Schuurman HJ, Cottens S, Fusch S y cols.: SDZ RAD, a new rapamycin derivative. Transplantation 64: 32-35, 1997.
28. Kelly P, Gruber SA, Behbod F, Kahan BD: Sirolimus: a new potent immunusuppressive agent. Pharmacotherapy 17: 1148-1156, 1997.
29. Vilella-Bach M, Nuzzi P, Fang Y, Chen J: The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin associated protein kinase activity and G1 progression. J Biol Chem 274: 4266-4272, 1999.
30. Schuurman HJ, Ringers J, Schuler W, Slingerland W, Jonker M: Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation 69: 737-742, 2000.
31. Schuurman HJ, Schuler W, Ringers J, Jonker M: The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc 30: 2198-2199, 1998.
32. Yamashita K, Hashimoto T, Kobayashi T, Nan H, Furukawa H, Todo S: Effect of new immunosuppressants RAD and FTY720 on rat liver transplantation: a transplant oddisey. Estambul, Turquía, 2001: FC 3.8.
33. Husen B, Boeke K, Berry GJ, Segarra IT, Christians U, Morris RE: Supresion of acute rejection in allogenic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion combination of cyclosporine. J Heart Lung Transplant 18: 150-159, 1999.
34. Hausen B, Boeke K, Berry GJ y cols.: Coadministration of Neoral and the novel rapamyci analog SDZ RAD, to rat lung allograft recipients. Transplantation 67: 956-962, 1999.
35. Hausen B, Boecke K, Berry GJ, Christians U, Schuler W, Morris RE: Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ RAD. Ann Thorac Surg 69: 904-909, 2000.
36. Hausen B, Ikonen T, Briffa N y cols.: Combined immunosuprression with cyclosporine (Neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation 69: 76-86, 2000.
37. Serkova N, Hausen B, Berry GJ y cols.: Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J Pharmacol Exp Ther 294: 323-332, 2000.
38. Hausen B, Gummert J, Berry GJ y cols.: Prevention of acute allograft rejection in non-human primate lung transplant recipients. Transplantation 69: 488-496, 2000.
39. Quesniaux VFJ, Menninger K, Kunkler A y cols.: The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T-and B-cells in cynomolgus monkeys when given alone, with cyclosporine Neoral or with RAD. Transplant Immunol 8: 177-187, 2000.
40. Niklova Z, Hof A, Baumlin Y, Hof RP: The peripheral lymphocyte count predicts graft survival in DA to Lewis heart transplantation treated with FTY720 and SDZ RAD. Transplant Immunol 8: 115-124, 2000.
41. Viklicky O, Zou H, Muller V, Lacha J, Szabo A, Herman U: SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 69: 497-502, 2000.
42. Lutz J, Zou H, Liu S, Antus B, Heemann U: Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 76: 508-515, 2003.
43. Cole OJ, Shehata M, Riggs KM: Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 30: 2200-2203, 1998.
44. Schuurman HJ, Pally C, Weckbecker G, Schuler W, Bruns C: SDZ RAD inhibits cold ischemia-induced vascular remodelling. Transplant Proc 31: 1024-1025, 1999.
45. Salminen US, Maasilta PK, Taskinen El, Alho HS, Ikonene TS, Harjula ALJ: Prevention of small airway obliteration in a seine heterotopic lung allograft model. J Heart Lung Transplant 19: 193-206, 2000.
46. Farb A, John M, Acampado E, Kolodgie FD, Prescott MF, Virmani R: Oral everolimus inhibits in-stend neointimal growth. Circulation 106: 2296-2298, 2002.
47. Nishimura T, Faul JL, Berry GJ, Veve I, Pearl RG , Kao PN: 40-O(2-Hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 163: 498-502, 2001.
48. Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, Sliberstein LE, Nowell PC, Schuler W, Shaw LM, Vasik MA: The immunosuppressive macrolide RAD inhibits growth of the human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of postrasplant lymphoproliferative disorders. Proc Natl Acad Sci USA 97: 4285-4290, 2000.
49. Majewski M, Korecka M, Joergensen J, Fields L, Kossev P, Schuler W, Shaw L, Wasik MA: Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from postrasplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 75: 1710-7, 2003.
50. Serkova N, Jacobsen W, Niemann CU, Litt L, Benet LZ, Leifritz D, Christians U: Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol 133: 875-885, 2001.
51. Kirchner GI, Winkler M, Mueller L y cols.: Pharmacokinetics of SDZ RAD and cyclosporine including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. Br J Clin Pharmacol 50: 449-454, 2000.
52. Kahan BD, Wong RL, Carter C, Katz SH, Von Fellengerg J, Van Buren CT, Appel-Dingemanse S: A phase I study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-treated renal transplant recipients. Transplantation 68: 1100-1106, 1999.
53. Neumayer HH, Paradis K, Korn A, Jean C, Fritsche L, Budde K, Winkler M, Kliem V, Pichlmayr R, Hauser IA, Burkhardt K, Lison AE, Barndt I, Appel-Dingemanse S: Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 48: 694-703, 1999.
54. Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M, Gerbeau C, Cambon N, Boger R, Rordorf C: Longitudinal assessment of everolimus in de novo renal transplant recipients over the first postrasplant year: Pharmacokinetics, exposure-response, relationship and influence on cylosporine. Clin Pharmacol Ther 69: 48-56, 2001.
55. Kovarik JM, Kaplan B, Silva HT, Kahan BD, Dantal J, Mac-Manon L, Berthier S, Hsu CH, Rordorf C: Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. Am J Transplant 3: 606-613, 2003.
56. Kovarik JM, Sabia H, Rouilly M y cols.: Influence of renal and hepatic impairment on everolimus pharmacokinetics: are dose adjustments necessary? Am J Transplant 1 (Supl. 1): 989, 2001.
57. Levy GA, Grant D, Paradis K, Campestrini J, Smith T, Kovarik JM: Pharmacokinetics and tolerability of 40-0-[2-hydroxiethyl]rapamycin in de novo liver transplant recipients. Transplantation 171: 160-163, 2001.
58. Levy G: A one-year, multicentre, randomized, placebo-controlled, double-blind, parallel group, dose-finding study to evaluate the safety, tolerability, and pharmacokinetics of RAD in de novo liver transplant recipients. 2001: a transplant Odyssey: the future is here. Estambul, Turquía S8.2, 2001.
59. Kirchner GI, Vidal C, Winkler M y cols.: LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolities, in human blood. Ther Drug Monitor 21: 116-122, 1999.
60. Kovarik JM, Kalbag J, Figueiredo J, Rouilly M, O'Bannon LF, Rordorf C: Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interction. J Clin Pharmacol 42: 95-99, 2002.
61. Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, Rordorf C: Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 36: 981-5, 2002.
62. Kahan BD, Kaplan B, Sorber MI, Winkler M, Cambon N, Boger RS: RAD in de novo renal transplantation: a comparison of three doses on the incidence and severity of acute rejection. Transplantation 171: 1400-1406, 2001.
63. Vitko S, Margreiter R, Weimar W y cols.: Everolimus (Certican TM) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation (in press).
64. Kaplan B, Tedesco-Silva H, Méndez R y cols.: North/South American double-blind, parallel-group study of the safety and efficacy of Certican versus mycophenolate mofetil in combination with Neoral and corticosteroids [Abstract]. Am J Transplant 1 (Supl. 1): 475, 2001.
65. Curtis J, Nashan B, Ponticelli C, Mourad G, Borger R y cols.: One year results of a multicenter open-label trial on safety and efficacy of certican (RAD) used in combination with Simulect, corticosteroids, and full or reduce dose Neoral in renal transplantation. Am J Transplant 1 (Supl. 1): 474, 2001.
66. Hoyer PF, Etternger R, Kovarik JM, Webb NJ, Lemire J, Mentser M, Mahan J, Loirat C, Niaudet P, Van Damme-Lombaerts R, Offner G, Wehr S, Moeller V, Mayer H: Everolimus in pediatric de novo renal transplant patients. Transplantation 75: 2082-5, 2003.
67. Kovarik JM, Kaplan B, Tedesco Silva H y cols.: Exposure-response relationship for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 73: 920-925, 2002.
68. Curtis J, Nashan B, Kovarik JM y cols.: RAD (everolimus) pharmacokinetics are unaltered with full-dose versus reduced-dose cyclosporine. Am J Transplant 1 (Supl. 1): 651 [Abstract], 2001.
69. Ponticelli C, Glotz D, Vialtel V y cols.: Certican TM with reduced dose Neoral results in a significantly higher GFR in de novo renal transplat recipients over the first 12 months compared with Certican-full dose Neoral as assessed by isohexol clearance. 2001: a transplant Odyssey. The future is here. Estambul. Turquía S18.2, 2001.
70. Mahalati K, Belitsky P, Sketris I, West K, Panek R: Neoral monitoring by simlified sparse sampling are under the concentration-time curve. Transplantation 68: 55-62, 1999.
71. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R: Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 12: 243-249, 1988.
72. International Neoral Renal Transplantation Study Group: Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2: 148-156, 2002.
73. International Neoral Renal Transplantation Study Group: Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2: 157-166, 2002.
74. Pascual J, Tedesco H, Civati G, Magee J, Haas T, Bernhardt P: Excellent renal function with concentration-controlled everolimus, reduced exposure to neoral and steroids in de novo kidney transplant recipients: resultad of a 6 months effciacy and safety analysis. Nephrol Dial Transplant 18 (Supl. 4): 786, 2003 [Abstract].
75. Kramer BK, Whelchel J, Eris J y cols.: Excellent graft function in de novo kidney transplant recipients treated with concentration-controlle everolimus, reduced neoral exposure and basiliximab: 6 months analysis. Nephrol Dial Transplant 18 (Supl. 4): 786 [Abstract].
76. Kahan BD: FTY720 in combination with RAD: a calcineurin antagonist-free maintenance immunosuppression strategy: 2003: a trasplanta odyssey. The future is here. Estambul, Turquía S12.5: 2001.
77. Eisen HJ, Tuzcu EM, Dorent R y cols.: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 349: 847-858, 2003.